Natco
Natco Pharma announces the appointment of Bhimrao Dattu Jadhav as Senior Vice President of Operations for its Formulations division, located in Kothur.Let me know if you’d like me to make any changes!
Natco Pharma Limited has named Bhimrao Dattu Jadhav as its new Senior Vice President – Operations (Formulations) for its Pharma Division – Kothur, effective March 3, 2025. With over 30 years of experience in operation management in the pharmaceutical industry, Jadhav brings a wealth of knowledge and expertise to his new role.
Prior to his appointment at Natco Pharma, Jadhav was the Senior Vice President Operations (Site Head) at INTAS Pharmaceutical Laboratories Ltd since 2018. Before that, he spent 19 years at Dr. Reddy’s Labs, where he held the position of Vice President Operations from 2006. Jadhav’s extensive experience in the pharmaceutical industry and his leadership skills make him a valuable addition to the Natco Pharma team.
Jadhav’s impressive background in operation management will be a significant asset to Natco Pharma as he will be responsible for overseeing the formulation operations within the Kothur division. His deep understanding of the industry and his ability to drive operational excellence will undoubtedly benefit the company. Additionally, his wealth of experience will be a valuable resource for the company as it looks to continue its growth and expansion in the industry. With Jadhav at the helm, Natco Pharma is well-positioned to achieve its objectives and continue to be a leading player in the pharmaceutical industry.
Natco Pharma welcomes G Vasan to its executive team as Vice President.
Ruchika Sharma is a correspondent for the Business Section at Medical Dialogue, a well-respected healthcare and pharmaceutical news website. She joined the team in 2019 and has since been responsible for covering all the latest updates in the pharmaceutical field, policy, insurance, business healthcare, medical news, health news, pharma news, and healthcare and investment. With her in-depth knowledge and expertise in the field, Ruchika provides readers with timely and accurate reports on the latest developments in the healthcare and pharmaceutical industries.
Ruchika holds a Bachelor’s degree in Commerce (B.Com) from Delhi University, where she developed a solid foundation in business and finance. She then went on to pursue her postgraduate degree in M.Com, further refining her knowledge and skills in the field.
With her strong educational background and experience in the healthcare industry, Ruchika is well-equipped to provide in-depth analysis and informed commentary on the complex issues and trends shaping the healthcare and pharmaceutical sectors. Her expertise has been recognized by the readers of Medical Dialogue, who value her insightful articles and subsequent analysis.
Ruchika can be contacted at editorial@medicaldialogues.in or on 011-43720751 for any questions, comments, or story pitches. As a correspondent for the Business Section, Ruchika is committed to providing her readers with the latest news, updates, and insights on the healthcare and pharmaceutical industries, helping them stay informed about the rapidly evolving landscape.
Natco Pharma’s CEO urges a proactive response to counter the impact of tariffs on front-end manufacturing in the US to mitigate potential disruptions to the pharmaceutical industry.
According to Natco Pharma’s Vice-Chairman and CEO Rajeev Nannapaneni, getting a front-end manufacturing foothold in the US could be the best solution for Indian generic drugmakers in the event of the US imposing tariffs on pharmaceuticals. Nannapaneni expressed this sentiment during a recent investor call, noting that if tariffs become a reality, they would have a significant impact on India’s pharmaceutical industry, which currently concentrates most of its manufacturing in the country. He believes that setting up a manufacturing base in the US would be a strategic move, but it would be limited to certain products that are feasible to produce in the country. However, he also mentioned that “you can’t do everything” due to production costs and other factors.
The company is considering acquiring prescription pharmaceutical businesses in the Rest of World (RoW) region and the US to strengthen its portfolio. As of December 31, 2024, Natco Pharma had a net cash balance of INR 3,000 crore. The company reported a consolidated net profit of INR 132.4 crore for the third quarter ended December, compared to INR 212.7 crore in the same period the previous year, with total revenue of INR 651.1 crore (INR 795.6 crore).
The statement comes as US President Donald Trump has announced plans to impose 25% tariffs on various imports, including pharmaceuticals, with the rate increasing progressively. Currently, the US has a zero-tariff regime on pharmaceuticals from India. Natco Pharma’s comments suggest that Indian generic drugmakers may need to reconsider their business strategies in response to the evolving tariff scenario.
Lupin and Cipla’s chronic therapies outperform acute medications in the long-term treatment of complex health conditions.
India’s top pharmaceutical companies delivered a mixed performance in the third quarter of fiscal 2025, with revenue growing 9% year-on-year and EBITDA and net profit rising 13% and 17%, respectively. Among the top performers were Lupin, Cipla, Sun Pharma, and Zydus LifeSciences, which beat analyst expectations and reported strong revenue and profit growth. On the other hand, Dr. Reddy’s Laboratories, Natco Pharma, Orchid Pharma, and Biocon underperformed, with Dr. Reddy’s reporting significant declines in profitability.
The domestic market saw a 7% rise in sales, driven by gains in cardiovascular, oncology, and dermatology therapies, while sales of anti-infective and respiratory drugs declined. Sun Pharma, Cipla, Lupin, Torrent, and Alkem benefited from the shift towards chronic treatments, while Alkem struggled with declining anti-infective sales.
In North America, revenues declined 3% year-on-year and sequentially, due to softer Revlimid sales and increased competition. However, contract development and manufacturing businesses performed well, led by strong growth at Divi’s Laboratories. Contract research organizations, on the other hand, faced pressure.
Research and development spending rose 9% year-on-year, accounting for 6.4% of total sales. Zydus, Lupin, and Dr. Reddy’s ramped up their research efforts, positioning themselves for future product launches, including semaglutide diabetes treatments in calendar 2026. With a strong US flu season expected, Lupin and Aurobindo Pharma are likely to benefit in the next quarter. Sun Pharma, with lower R&D spending and seasonal demand, could also post strong fourth-quarter results. However, the anticipated decline in Revlimid sales by mid-FY26 remains a concern for generic drugmakers.